| Course | NR 511 Differential Diagnosis and Primary Care Practicum |
|---|---|
| Week | 6 |
| Paper type | Chronic care follow-up note |
| Length | About 1,230 words, 6 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Family Nurse Practitioner (FNP) |
| Updated | September 2026 |
Free sample paper for NR 511 Week 6
Chronic Care Note: A Lean 41-Year-Old Whose Type 2 Diabetes Stopped Responding to Two Tablets, the Four Explanations for a Rising A1c, and Why the Label in the Chart Is Being Reopened
Student Name
College of Nursing, Chamberlain University
NR 511: Differential Diagnosis and Primary Care Practicum
Instructor Name
Month Day, Year
Chronic Care Note: A Lean 41-Year-Old Whose Type 2 Diabetes Stopped Responding to Two Tablets, the Four Explanations for a Rising A1c, and Why the Label in the Chart Is Being Reopened
Subjective
Reason for visit: Three-month diabetes follow-up. "My sugars are climbing again and I'm thirsty all the time, even though I'm doing everything right."
Interval history: Mr. D. M. is a 41-year-old warehouse supervisor who was diagnosed with type 2 diabetes 14 months ago, when a workplace screening found a random glucose of 286 mg/dL and a hemoglobin A1c of 8.2%. He was started on metformin, which was increased to 1,000 mg twice daily. His A1c fell to 7.1% at four months. At eight months it had risen to 7.8%, and glipizide 5 mg daily was added. Since the last visit he reports thirst, waking twice each night to pass urine and losing about 9 pounds without trying. He denies nausea, vomiting, abdominal pain, fever, a recent infection, new medications and steroid use. He has not changed his diet; he brings a food log that shows regular meals with modest portions. He has no symptoms of low blood sugar.
Adherence: He uses a weekly pill organizer. The pharmacy refill record shows both medications filled on time for the past six months. He tolerates metformin without stomach upset.
PMH: No hypertension or hyperlipidemia. Family history: Mother with hypothyroidism on levothyroxine since her thirties; a maternal aunt with vitiligo. No family history of diabetes in either parent. Social: Never smoker; drinks rarely; walks about 12,000 steps on shifts.
Objective
Vitals and trend: Weight 158 lb today; 167 lb three months ago; 169 lb at diagnosis. BMI 23.1 today, 24.4 at diagnosis. Blood pressure 118/74 mm Hg, unchanged. Heart rate 84.
Laboratory trend: Hemoglobin A1c 8.2% at diagnosis, 7.1% at four months, 7.8% at eight months, and 8.9% today. Point-of-care glucose today 247 mg/dL, two hours after lunch. Urine dipstick: glucose 3+, ketones trace, protein negative.
Examination: Mucous membranes slightly dry. No acanthosis nigricans on the neck or axillae. Thyroid not enlarged. Heart and lungs normal. Abdomen soft and nontender with no mass. Monofilament sensation intact in both feet; no foot lesions. Skin: a small patch of depigmentation on the back of the left hand that he says appeared last year.
Assessment
Problem 1: Diabetes with worsening control despite adherence, and unintended weight loss. The chart label, type 2 diabetes, is reopened.
The label was reasonable at diagnosis: an adult, no ketosis, and a good first response to metformin. The question this visit asks is whether the response since then still fits it. It does not fit well. Type 2 diabetes can progress, but a lean man losing weight while his glucose rises within 14 months, on two drugs taken reliably, is not the usual course. Four explanations are weighed.
a. Nonadherence or a change in diet. Commonly the cause of a rising A1c. Weakened here by a pharmacy record of on-time fills, a pill organizer and a food log with no change. Moved down.
b. Progressive type 2 diabetes. Possible, since beta-cell function declines over time in type 2 diabetes. Weakened by his normal BMI, no acanthosis nigricans, no hypertension or lipid disorder, no family history of type 2 diabetes, and the speed of the change.
c. Latent autoimmune diabetes in adults (LADA) or adult-onset type 1 diabetes. Raised by lean body build, weight loss with rising glucose, trace ketones, early failure of oral agents, and a personal and family history of autoimmune conditions: his mother's hypothyroidism, his aunt's vitiligo and his own new patch of depigmentation. Buzzetti et al. (2020) describe LADA as a slowly progressing autoimmune diabetes in adults who do not need insulin at diagnosis and who can look clinically like type 2 diabetes, and they estimate it accounts for 2% to 12% of adult-onset diabetes. Leslie et al. (2021) note that adults with type 1 diabetes may not need insulin at first, which leads to misclassification and inappropriate treatment.
d. Diabetes secondary to pancreatic disease. New or worsening diabetes with weight loss can signal pancreatic disease, including cancer. Weakened by his age, no abdominal pain, no alcohol excess, no steatorrhea and a normal abdominal examination. Kept on the list with a trigger, not investigated today.
Revised ranking: (1) LADA or adult-onset type 1 diabetes; (2) progressive type 2 diabetes; (3) pancreatic disease; (4) nonadherence. The original diagnosis moves from first to second, for the reasons given above.
Problem 2: Mild volume depletion with glycosuria and trace ketonuria. Not in ketoacidosis: he is alert, not vomiting, and has only trace ketones, but the trend is the one that leads there if insulin deficiency is the cause.
Plan
Problem 1.
Diagnostics. Glutamic acid decarboxylase (GAD) antibodies and a random C-peptide drawn with a paired glucose today; thyroid-stimulating hormone given his family history. Buzzetti et al. (2020) advise screening for LADA in adults newly diagnosed with non-insulin-requiring diabetes and use C-peptide to guide treatment: below 0.3 nmol/L, a multiple-dose insulin regimen as for type 1 diabetes; 0.3 to 0.7 nmol/L, a gray area where insulin is considered alongside other agents; above 0.7 nmol/L, an approach close to that for type 2 diabetes, with C-peptide monitored over time. The antibody result answers the reopened question directly: positive GAD antibodies would confirm autoimmune diabetes; negative antibodies with a preserved C-peptide would move type 2 diabetes back to first place.
Therapeutics, one change. Basal insulin glargine 10 units at bedtime, with a fasting glucose target of 80 to 130 mg/dL and a simple titration rule: raise by 2 units every three days if the fasting reading is above 130. Metformin and glipizide are left unchanged until the antibody and C-peptide results return next week, so that the next reading can be attributed to the insulin. If antibodies are positive, glipizide will be stopped, since the consensus panel advises against sulfonylureas in LADA because of concern about beta-cell decline (Buzzetti et al., 2020).
Education. Insulin injection technique, taught back with a pen device in the visit. Recognition and treatment of low blood sugar, including the rule of 15 grams of fast carbohydrate. Explained honestly why his diagnosis is being reconsidered and that this is a question, not a failure on his part.
Follow-up. Nurse phone call in three days for fasting readings. Visit in one week for results; if autoimmune diabetes is confirmed, referral to endocrinology and diabetes education for a type 1 care plan, following the joint American Diabetes Association and European Association for the Study of Diabetes consensus for adults with type 1 diabetes (Holt et al., 2021).
Problem 2.
Therapeutics and education. Drink water freely; avoid sugary drinks. Diagnostics. Home urine ketone strips provided. Trigger. Go to the emergency department for vomiting, abdominal pain, rapid breathing, confusion or moderate or large urine ketones, any of which could signal diabetic ketoacidosis.
Problem 1, candidate d, trigger. If antibodies are negative and C-peptide is low, or if weight loss continues once glucose is controlled, or if abdominal pain or jaundice appears, pancreatic imaging will be ordered.
References
Buzzetti, R., Tuomi, T., Mauricio, D., Pietropaolo, M., Zhou, Z., Pozzilli, P., & Leslie, R. D. (2020). Management of latent autoimmune diabetes in adults: A consensus statement from an international expert panel. Diabetes, 69(10), 2037-2047. https://doi.org/10.2337/dbi20-0017
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., Skyler, J. S., Snoek, F. J., Weinstock, R. S., & Peters, A. L. (2021). The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 44(11), 2589-2625. https://doi.org/10.2337/dci21-0043
Leslie, R. D., Evans-Molina, C., Freund-Brown, J., Buzzetti, R., Dabelea, D., Gillespie, K. M., Goland, R., Jones, A. G., Kacher, M., Phillips, L. S., Rolandsson, O., Wardian, J. L., & Dunne, J. L. (2021). Adult-onset type 1 diabetes: Current understanding and challenges. Diabetes Care, 44(11), 2449-2456. https://doi.org/10.2337/dc21-0770
Reading the NR 511 Week 6 instructions
The Week 6 assignment centers on a follow-up visit for a chronic condition. You document interval history, adherence, treatment response and current findings, then assess whether the condition is controlled and whether the diagnosis and plan still fit. Most prompts ask for guideline-based management changes, patient education, monitoring and a follow-up interval. Some versions give a patient whose control has slipped and ask you to explain why. The skill being graded is clinical judgment over time: using trends, not single values, and asking whether the chart diagnosis is right before simply adding another drug. Cite current guidelines for the condition.
Inside the NR 511 Week 6 example
The note opens with the reason for the visit and an interval history that tests adherence with evidence rather than the patient's word alone. The objective section lists weight and A1c at each visit, so the reader sees glucose rising as weight falls. The assessment explains why the original label was reasonable and why the response no longer fits it, then weighs nonadherence, progressive type 2 diabetes, latent autoimmune diabetes and pancreatic disease. The ranking moves with stated reasons. The plan draws GAD antibodies and C-peptide, uses consensus C-peptide thresholds to guide what comes next, adds one drug, and sets ketone and pancreatic triggers.
Reading the NR 511 Week 6 grading rubric
Rubrics for the chronic care note usually reward accurate assessment of control, use of trend data, and management that follows current guidelines. The largest share often goes to the assessment, so a note that restates the diagnosis without asking whether it still fits will fall short. Graders look for a clear reason for any change in treatment, safe prescribing with monitoring, and specific education. Follow-up earns points when it names an interval and what should prompt earlier contact. Evidence from consensus statements or guidelines supports the decisions. Organization and APA 7 format make up the remaining points, as in the other NR 511 notes. A strong note also shows that the student considered a different diagnosis before escalating treatment.
NR 511 Week 6 help: mistakes that cost points
The mistake that costs most here is documenting around the chart diagnosis, adding a third drug for diabetes without asking why the first two failed. Another is listing possible causes of poor control without examining any of them, such as adherence. Students also report a single lab value with no comparison, which hides the trend the visit is about. Plans that change several medications at once are hard to evaluate at the next visit. Finally, do not forget safety: new insulin needs hypoglycemia teaching, and a patient with ketones needs clear emergency triggers. Show your reasoning for keeping or changing each part of the plan. A short sentence explaining why you kept a drug is worth as much as one explaining why you stopped another.
Get a NR 511 Week 6 example written to your instructions
Send the scenario your section gave you, the rubric, and any chronic care template your classroom requires. We write a custom NR 511 Week 6 example to match, turned around inside 24-48h, with nothing to pay on the first one. It comes back with the reasoning about the earlier diagnosis written out rather than assumed.
More NR 511 papers and FNP samples
- NR 511 Week 1: Discussion Post on Facial Pain
- NR 511 Week 2: Focused SOAP Note, Flashes, Floaters
- NR 511 Week 3: Differential for Chronic Cough
- NR 511 Week 4: Case Analysis, Acute Knee Swelling
- NR 511 Week 5: SOAP Note, Polymyalgia Rheumatica
- NR 511 Week 7: Case Study Analysis
- NR 511 Week 8: Practice Reflection
NR 511 Week 6 questions, answered
Does reconsidering a diagnosis mean the first one was wrong?
Not necessarily, and the example says so. A working diagnosis can remain the best explanation while the response to treatment raises a second problem alongside it. What earns points is the act of testing the fit and stating the result, whether the ranking changes or stays where it was.
How much interval history is enough?
Enough to explain the response. The example covers what was taken and what was missed, what improved and what did not, and any new complaint since the last visit. A one-line summary saves space and then leaves the assessment unable to separate a treatment failure from a diagnosis that never fitted.
What if the section supplies a chronic care template?
Use it. Templates set the headings and the order, not the reasoning, and the example maps cleanly onto most of them. Where a template offers no obvious place for the reconsideration, it usually belongs in the assessment, written as a short paragraph before the revised problem list.
Where can I find a free NR 511 Week 6 sample paper?
This page carries a complete NR 511 Week 6 chronic care note on a reopened diabetes diagnosis, free to read. If your follow-up patient has a different chronic condition, describe that patient on the request page and a free version is written around their case.
What chronic conditions suit the NR 511 Week 6 note?
Hypertension, diabetes, asthma, COPD, thyroid disease and hyperlipidemia are common choices. The note is strongest when the patient's response to treatment raises a real question, as the rising A1c does in the sample.